Found 296 of Enz. Inhib. data with enzyme = 'Proto-oncogene tyrosine-protein kinase Src' and Substrate = 'Poly(E:Y)'
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 5.68nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 6nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 7.40nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 7.5nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 8nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 8nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 8.35nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 9.03nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 10nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 12nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 12nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 13nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 14nMAssay Description:Compounds were evaluated for their ability to prevent phosphorylation of a model glutamate-tyrosine copolymer substrate by isolated human FGFR-1, mou...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 14nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 14nMAssay Description:Compounds were evaluated for their ability to prevent phosphorylation of a model glutamate-tyrosine copolymer substrate by isolated human FGFR-1, mou...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 15nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 15nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16.3nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 16.8nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 17nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 17nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 18nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 19nMAssay Description:Compounds were evaluated for their ability to prevent phosphorylation of a model glutamate-tyrosine copolymer substrate by isolated human FGFR-1, mou...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 19nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 19nMAssay Description:Compounds were evaluated for their ability to prevent phosphorylation of a model glutamate-tyrosine copolymer substrate by isolated human FGFR-1, mou...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 20nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 20nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 20nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 20nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 20nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 22nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 22nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 22nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 22nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 24nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 24.5nMpH: 7.5 T: 2°CAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 29nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 30nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Parke-Davis Pharmaceutical Research
Parke-Davis Pharmaceutical Research
Affinity DataIC50: 31nMAssay Description:IC50 is the inhibitor concentration which inhibits 50% of kinase activity that catalyzes the transfer of the terminal phosphate from [gamma-32P] labe...More data for this Ligand-Target Pair